Can a clotting factor stop bleeding in ECMO patients?

NCT ID NCT06118372

Recruiting now Disease control Sponsor: University of Virginia Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a single dose of a lab-made clotting protein (recombinant von Willebrand factor) in 12 adult patients on ECMO who have major bleeding. The goal is to see if the drug is safe and how it behaves in the body. If successful, it may lead to a new way to control bleeding in this high-risk group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Recombinant von Willebrand Factor (a lab-made blood clotting protein)
What this could lead to: If it works, this could point toward a treatment to control severe bleeding in ECMO patients, potentially reducing complications and improving survival.
What could go wrong: This is a very early, small phase I trial with only 12 participants, so results may not apply to all patients. The drug could cause serious side effects or fail to stop bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACQUIRED VON WILLEBRAND SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired von willebrand syndrome hemorrhagic disease vascular hemostatic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLEEDING DISORDER

Contacts and locations

Locations

UVA Hospital
RECRUITING

Charlottesville, Virginia, 22903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.